We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Glucose Biosensor Introduced for Diabetes Management

By LabMedica International staff writers
Posted on 11 Feb 2019
Print article
Image: The Saliva Glucose Biosensor that measures glucose in saliva rather than blood (Photo courtesy of iQ Group Global).
Image: The Saliva Glucose Biosensor that measures glucose in saliva rather than blood (Photo courtesy of iQ Group Global).
The world’s first saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood has been introduced. The core scientific innovation of the biosensor lies in the patent protected modified organic thin film transistor architecture, incorporating Glucose Oxidase (GOX) as the recognition element to initiate an electrochemical reaction that produces an electrical signal.

This electrical signal can be displayed on the patient’s smart device in real time. The biosensor exhibits high sensitivity hence is able to detect glucose levels at considerably lower levels than in blood. It has a linear glucose sensing capability at concentrations of 100 times lower than current blood measuring methodologies.

The Saliva Glucose Biosensor (iQ Group Global, Sydney, Australia) is comprised of the Glucose Biosensor Unit and a digital healthcare app. The Glucose Biosensor Unit is a small, disposable strip, which when exposed to an individual’s saliva instantly provides a glucose measurement. The glucose measurement will be presented in real-time, via a proprietary digital app on a patient’s smart device.

The glucose measurement recorded by the biosensor will be presented via the proprietary digital app on the patient’s smart device in real-time where the patients may also compare historic glucose levels. This will open significant opportunities to improve the way diabetes is monitored and managed, enabling patients to store and analyze their data, share monitoring data with their healthcare team or relatives, create and send automated reminders when it is time to test glucose levels, offer educational services, and act as a provider for healthcare companies who offer patient support programs.

George Syrmalis, PhD, Chief Executive Officer and Chairman of the iQ Group Global, said, “Diabetes is a global epidemic, with 1 in 11 adults living with the disease. Achieving normoglycemia is one of the main targets for diabetes patients. However, finger prick testing is a painful and frustrating process, with many citing the pain as the main reason for poor adherence to testing protocols. By eradicating the need for finger prick blood tests, the saliva-based test will lead to increased glucose monitoring and better healthcare outcomes among these patients.”

Related Links:
iQ Group Global

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more